We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Collaboration to Focus on Women’s Health Diagnostic Solutions

By LabMedica International staff writers
Posted on 18 Jun 2013
Two companies have entered into a collaboration that will feature the national availability of a cervical cancer-screening test in addition to developing and expanding access to diagnostic solutions for women’s health.

Quest Diagnostics (Madison, N.J. More...
USA), a global diagnostic information services company, and Hologic, Inc. (Bedford, MA, USA), a developer, manufacturer, and supplier of diagnostics products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women, have entered into a strategic alliance to more broadly offer testing based on Hologic’s Aptima range of products, as well as to codevelop and promote advanced diagnostic solutions to improve women's health.

Under the nonexclusive agreement, which has an initial term of five years, the companies will focus primarily on clinical areas critical to the health of women. Quest Diagnostics will develop a broader offering of services based on Hologic’s Aptima family of products, which includes US Food and Drug Administration (FDA; Silver Spring, MD, USA)-approved or cleared assays for human papillomavirus (HPV), HPV genotyping, Chlamydia, gonorrhea, and Trichomonas vaginalis. In addition, Quest Diagnostics will continue to utilize Hologic's leading line of ThinPrep liquid-based cytology products.

Quest Diagnostics will also continue to offer Hologic’s Aptima HPV mRNA-based assay nationally. The Aptima HPV assay detects messenger RNA overexpressed from two viral oncogenes that are integral to the development of cervical cancer. Hologic’s Aptima HPV assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens.

The companies will also explore opportunities to develop and expand access to new diagnostic solutions for women’s health. In addition, they will implement joint programs to advance women’s health issues with medical associations and patient advocacy groups and to sponsor research. Financial terms of the collaboration were not disclosed.

“Our relationship with Hologic also demonstrates our progress executing on our restore growth and operational excellence strategies,” said Mr. Rusckowski, Quest’s CEO. “With this alliance, we will strengthen the specialization and competitiveness of our women's health business. We are also working more closely and strategically with suppliers, and this alliance is the first under our new, highly rigorous supplier engagement model, which we unveiled at our first ever Supplier Forum in March.”

Related Links:

Quest Diagnostics
Hologic
US Food and Drug Administration



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.